Atle Fund Management AB
Long book
$309.7M
Q1 2026
Positions
39
Top-10 weight
45%
concentration
Last quarter
+17.3%
SPY +14.8%
Turnover
19%
of book per quarter
Strategy in plain words
auto-generated from filingsAtle Fund Management AB is a concentrated fundamental stock-picker, specialised in healthcare (91% of the long book), running a $309.7M US long book across 39 positions.
The portfolio is moderately concentrated (top 10 ≈ 45% of the book). Turnover is modest: positions are typically held for years. Current anchor positions: ELI LILLY & CO, MERCK & CO. INC., THERMO FISHER SCIENTIFIC INC, BEONE MEDICINES LTD-ADR, JOHNSON & JOHNSON.
Over the last 9 quarters its long book ran on average 1.6pp per quarter behind the S&P 500, beating the index in 3 of 9 quarters. We rate its filings highest-signal: new buys here are worth attention.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
-1.8%
Q2 2024
+1.6%
Q3 2024
-8.4%
Q4 2024
+4.2%
Q1 2025
-3.2%
Q2 2025
+5.5%
Q3 2025
+15.3%
Q4 2025
-4.7%
Q1 2026
+17.3%
Sector allocation
Healthcare 89%
Other 6%
Consumer discretionary 4%
Financials 1%
Long book by quarter
What does Atle Fund own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| LLY ELI LILLY & CO | Healthcare | 39.7K | $26.8M | 8.7% | +27.6% |
| MRK MERCK & CO. INC. | Healthcare | 33.9K | $22.9M | 7.4% | -82.7% |
| TMO THERMO FISHER SCIENTIFIC INC | Other | 23.0K | $14.4M | 4.7% | -23.2% |
| JNJ JOHNSON & JOHNSON | Healthcare | 92.4K | $11.9M | 3.9% | New |
| BBIO BRIDGEBIO PHARMA INC | Healthcare | 111.4K | $11.9M | 3.8% | -21.2% |
| VRTX VERTEX PHARMACEUTICALS INC | Healthcare | 23.0K | $11.2M | 3.6% | Held |
| ABBV ABBVIE INC | Healthcare | 108.2K | $10.4M | 3.4% | Held |
| SYK STRYKER CORP | Healthcare | 26.8K | $9.6M | 3.1% | Held |
| ISRG INTUITIVE SURGICAL INC | Healthcare | 70.9K | $9.4M | 3.0% | +217.4% |
| IONS IONIS PHARMACEUTICALS INC | Healthcare | 27.9K | $9.4M | 3.0% | -69.8% |
| MIRM MIRUM PHARMACEUTICALS INC | Healthcare | 195.8K | $9.4M | 3.0% | +118.3% |
| CVS CVS HEALTH CORP | Healthcare | 23.8K | $9.3M | 3.0% | -77.7% |
| RVMD REVOLUTION MEDICINES INC | Healthcare | 617.2K | $9.1M | 2.9% | +584.4% |
| BSX BOSTON SCIENTIFIC CORP | Healthcare | 40.4K | $8.8M | 2.9% | -62.8% |
| AMGN AMGEN INC | Healthcare | 21.9K | $8.7M | 2.8% | Held |
| EW EDWARDS LIFESCIENCES CORP | Healthcare | 106.5K | $8.3M | 2.7% | New |
| ALKS ALKERMES PLC | Healthcare | 242.5K | $8.2M | 2.7% | Held |
| INCY INCYTE CORP | Healthcare | 50.8K | $8.0M | 2.6% | -28.3% |
| NBIX NEUROCRINE BIOSCIENCES INC | Healthcare | 89.7K | $7.9M | 2.5% | -5.4% |
| GILD GILEAD SCIENCES INC | Healthcare | 48.0K | $7.2M | 2.3% | -5.6% |
| KRYS KRYSTAL BIOTECH INC | Healthcare | 37.6K | $6.8M | 2.2% | +11.0% |
| COR CENCORA INC | Consumer discretionary | 23.5K | $6.6M | 2.1% | -1.3% |
| IRTC IRHYTHM HOLDINGS INC | Healthcare | 22.3K | $6.3M | 2.0% | -40.6% |
| INSM INSMED INC | Healthcare | 97.4K | $6.0M | 1.9% | +249.6% |
| NAMS NEWAMSTERDAM PHARMA CO NV | Healthcare | 94.8K | $5.5M | 1.8% | -51.9% |
| CELC CELCUITY INC | Healthcare | 141.3K | $5.1M | 1.7% | +237.8% |
| CAH CARDINAL HEALTH INC | Consumer discretionary | 108.7K | $4.8M | 1.5% | +363.1% |
| IDYA IDEAYA BIOSCIENCES INC | Healthcare | 31.1K | $4.0M | 1.3% | -68.0% |
| TNGX TANGO THERAPEUTICS INC | Healthcare | 29.9K | $3.6M | 1.2% | New |
| SYRE SPYRE THERAPEUTICS INC | Healthcare | 62.7K | $3.5M | 1.1% | New |
| IRON DISC MEDICINE INC | Healthcare | 107.3K | $3.2M | 1.0% | +123.6% |
| CMPX COMPASS THERAPEUTICS INC | Healthcare | 41.8K | $3.1M | 1.0% | -92.8% |
| UNH UNITEDHEALTH GROUP INC | Financials | 14.6K | $2.8M | 0.9% | Held |
| DXCM DEXCOM INC | Healthcare | 584.3K | $2.6M | 0.9% | +1371.1% |
| BCAX BICARA THERAPEUTICS INC | Healthcare | 1.2M | $2.3M | 0.7% | +950.3% |
| SLNOEUR SOLENO THERAPEUTICS INC | — | 90.2K | $2.2M | 0.7% | +43.8% |
| PYXS PYXIS ONCOLOGY INC | Healthcare | 197.0K | $1.6M | 0.5% | -68.1% |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 11, 2026 | 39 | $309.7M | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 6, 2026 | 39 | $313.4M | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 4, 2025 | 38 | $27.0M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Jul 14, 2025 | 37 | $233.7M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 5, 2025 | 37 | $226.5M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 4, 2025 | 36 | $210.8M | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 12, 2024 | 36 | $212.8M | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Aug 14, 2024 | 38 | $164.0M | canonical | SEC ↗ |
| Q1 2024 | 13F-HR | Apr 25, 2024 | 44 | $164.4M | canonical | SEC ↗ |